Grant: Catalyst Grant: Systems Biology Approaches to Immunotherapy
University of Victoria (British Columbia)
$100,000.00
The Ovarian Cancer Immune Epitope Database
EF 2008-09
Résumé
The MHC class I peptide (MIP) repertoire comprises a collection of peptides that are presented at the cell surface in the context of MHC class I molecules for scrutiny by cells of the CD8+ lineage. Under conditions of microbial infection, CD8 T cell responses specific for pathogen-derived MIP peptides are elicited and these antigen-specific cells are primarily responsible for eradicating infection. However, under normal, steady-state conditions, peptides derived from "self" proteins are continually degraded as part of the constitutive activity of the proteasome and are presented on the cell surface as the "self" MIP repertoire. Likewise, tumor-associated antigens expressed by cancer cells are processed to become part of the cancer MIP repertoire and in doing so represent ideal target antigens for potential immunotherapeutic intervention. Despite the tremendous potential importance of the cancer MIP repertoire, relatively little is known about its composition or complexity. In the current proposal we intend to catalogue the MIP repertoire present on the surface of ovarian cancer cells. Specifically, we will utilize malignant ascites samples from patients with stage III-IV ovarian cancer as a source of cells for mass spectrometry-based identification of MHC-associated peptides. Malignant ascites removed from ovarian cancer patients via paracentesis, or as part of de-bulking surgery, frequently contains extraordinary numbers of tumor cells (>108) which can be readily purified from any infiltrating immune cells. Two complimentary approaches for peptide purification will be utilized, 1) peptides will be directly eluted from surface MHC using mild acid treatment and 2) peptides will be acid eluted from specific MHC molecules that have been immuno-precipitated from tumor cell lysates. Peptides isolated using these approaches will be identified by tandem mass spectrometric approaches and a database corresponding to the ovarian cancer MIP repertoire will be established.
Programme
Catalyst Grant: Systems Biology Approaches to Immunotherapy
Bénéficiaire
Emplacement
British Columbia, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
172933
Name
Webb John R
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Systems Biology Approaches to Immunotherapy
Projecttitle
The Ovarian Cancer Immune Epitope Database
Programtype2
Operating Grants
Orgnameinp2
University of Victoria (British Columbia)
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Systems Biology Approaches to Immunotherapy
Keyworddelim
Cancer; Immunology; Immunotherapy; Mass Spectrometry; Peptide
Abstract
The MHC class I peptide (MIP) repertoire comprises a collection of peptides that are presented at the cell surface in the context of MHC class I molecules for scrutiny by cells of the CD8+ lineage. Under conditions of microbial infection, CD8 T cell responses specific for pathogen-derived MIP peptides are elicited and these antigen-specific cells are primarily responsible for eradicating infection. However, under normal, steady-state conditions, peptides derived from "self" proteins are continually degraded as part of the constitutive activity of the proteasome and are presented on the cell surface as the "self" MIP repertoire. Likewise, tumor-associated antigens expressed by cancer cells are processed to become part of the cancer MIP repertoire and in doing so represent ideal target antigens for potential immunotherapeutic intervention. Despite the tremendous potential importance of the cancer MIP repertoire, relatively little is known about its composition or complexity. In the current proposal we intend to catalogue the MIP repertoire present on the surface of ovarian cancer cells. Specifically, we will utilize malignant ascites samples from patients with stage III-IV ovarian cancer as a source of cells for mass spectrometry-based identification of MHC-associated peptides. Malignant ascites removed from ovarian cancer patients via paracentesis, or as part of de-bulking surgery, frequently contains extraordinary numbers of tumor cells (>108) which can be readily purified from any infiltrating immune cells. Two complimentary approaches for peptide purification will be utilized, 1) peptides will be directly eluted from surface MHC using mild acid treatment and 2) peptides will be acid eluted from specific MHC molecules that have been immuno-precipitated from tumor cell lysates. Peptides isolated using these approaches will be identified by tandem mass spectrometric approaches and a database corresponding to the ovarian cancer MIP repertoire will be established.
Competitiondate
200808
Approvedterm2
1 yr 0 mth
Pinamesdelim
Webb, John R
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $100,000~ $0~